This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Fred Hutchinson Cancer Center, Massachusetts Institute of Technology. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 309 
1 out of 8,600 
Years Active: 2024
Title: Innovations of Yukang Lin in Hematological Malignancies
Introduction
Yukang Lin is a notable inventor based in Issaquah, Washington, who has made significant contributions to the field of medical research, particularly in the treatment of hematological malignancies. His innovative work focuses on the development of bispecific antibodies that enhance therapeutic options for patients suffering from various blood disorders.
Latest Patents
Yukang Lin holds a patent for bispecific antibodies specifically designed for treating hematological malignancies. The patent outlines compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) aimed at addressing various hematological disorders, including B cell hyperproliferative disorders and solid tumors. The disclosed compositions feature bispecific antibody compositions that include a first domain binding to antigens such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that binds to a radioactive ligand. The methods described involve administering the bispecific antibody reagent alongside the radioactive ligand, with potential inclusion of a clearing agent and enhancing agents to improve target antigen expression on cells.
Career Highlights
Throughout his career, Yukang Lin has worked with prestigious institutions, including the Fred Hutchinson Cancer Center and the Massachusetts Institute of Technology. His research has contributed to advancements in the understanding and treatment of hematological disorders, showcasing his commitment to improving patient outcomes through innovative therapies.
Collaborations
Yukang Lin has collaborated with esteemed colleagues, including Damian J. Green and Oliver Press, to further his research and development efforts in the field of hematological malignancies.
Conclusion
Yukang Lin's contributions to the field of medical research, particularly through his patent on bispecific antibodies, highlight his role as an innovator in the treatment of hematological malignancies. His work continues to pave the way for new therapeutic strategies that can significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile